Identification of TRPC6 as a possible candidate target gene within an amplicon at 11q21-q22.2 for migratory capacity in head and neck squamous cell carcinomas
© Bernaldo de Quirós et al.; licensee BioMed Central Ltd. 2013
Received: 5 October 2012
Accepted: 7 March 2013
Published: 14 March 2013
Cytogenetic and gene expression analyses in head and neck squamous cell carcinomas (HNSCC) have allowed identification of genomic aberrations that may contribute to cancer pathophysiology. Nevertheless, the molecular consequences of numerous genetic alterations still remain unclear.
To identify novel genes implicated in HNSCC pathogenesis, we analyzed the genomic alterations present in five HNSCC-derived cell lines by array CGH, and compared high level focal gene amplifications with gene expression levels to identify genes whose expression is directly impacted by these genetic events. Next, we knocked down TRPC6, one of the most highly amplified and over-expressed genes, to characterize the biological roles of TRPC6 in carcinogenesis. Finally, real time PCR was performed to determine TRPC6 gene dosage and mRNA levels in normal mucosa and human HNSCC tissues.
The data showed that the HNSCC-derived cell lines carry most of the recurrent genomic abnormalities previously described in primary tumors. High-level genomic amplifications were found at four chromosomal sites (11q21-q22.2, 18p11.31-p11.21, 19p13.2-p13.13, and 21q11) with associated gene expression changes in selective candidate genes suggesting that they may play an important role in the malignant behavior of HNSCC. One of the most dramatic alterations of gene transcription involved the TRPC6 gene (located at 11q21-q22.2) which has been recently implicated in tumour invasiveness. siRNA-induced knockdown of TRPC6 expression in HNSCC-derived cells dramatically inhibited HNSCC-cell invasion but did not significantly alter cell proliferation. Importantly, amplification and concomitant overexpression of TRPC6 was also found in HNSCC tumour samples.
Altogether, these data show that TRPC6 is likely to be a target for 11q21–22.2 amplification that confers enhanced invasive behavior to HNSCC cells. Therefore, TRPC6 may be a promising therapeutic target in the treatment of HNSCC.
KeywordsHead and neck squamous cell carcinoma TRPC6 Invasion Gene amplification
The broad application of cytogenetic and molecular genetics methods has led to the identification of tumor-associated chromosomal regions substantial for the tumorigenesis and progression of head and neck squamous cell carcinomas (HNSCC) [1–3]. Comprehensive analysis of recurrent amplified chromosomal regions has allowed identification of oncogenes and other cancer-related gene such as EMS1, CCND1, PPFIA1, TAOS1 (11q13), LOXL4 (10q24), PAK4 (19q13), and HIF1A (14q23-q24) which have been associated with different clinical behaviors [4–10]. Therefore, associations of high-level genomic amplifications with altered gene expression and functional analysis of the affected genes represents an excellent approach to identify novel genes involved in tumor progression and carcinogenesis.
Here, we compared the genome-wide DNA copy number alterations present in five HNSCC-derived cell lines with those previously reported in tumour tissues. Remarkably, our data showed that the cell lines analyzed here resemble most of the important genomic alterations previously described in primary HNSCC. It also revealed the presence of several regions with high level focal amplifications (11q21-22.2, 18p11.31-p11.21, 19p13.2-p13.13, and 21q11) that have been previously identified in HNSCC [1, 11].
Although rarely detected in solid tumors, high level amplification at 11q22-q23 has been described not only in HNSCC [12, 13] but in many malignancies including glioblastomas, renal cell carcinomas, sarcomas, and cervical, lung and pancreatic cancers [14–19] thus suggesting that this region may harbor gene(s) that, when amplified, have an active role in tumorigenesis and/or cancer progression. YAP gene has been identified as a candidate target gene in 11q22 amplicon in several human cancers [20–22]. However, to date, no specific genes have been proposed as targets in HNSCC.
In the present report, we performed gene expression analysis of the amplified genes in each amplicon identified in HNSCC-derived cell lines what allowed the identification of 12 novel genes with potential implications in HNSCC biology. One of the most dramatically amplified and overexpressed gene identified here is TRPC6, a member of the transient receptor potential (TRPC) subfamily, located at 11q22.1. This novel genetic change was also identified in primary HNSCC-tumour samples. Remarkably, recent studies have revealed that TRPC6 has an essential role in glioma growth, invasion, and angiogenesis [23, 24]. We show here that TRPC6 overexpression confers enhanced invasive behavior to HNSCC cells. Therefore, TRPC6 may have an essential role in the development of the aggressive phenotype of HNSCC and may be a promising therapeutic target in the treatment of HNSCC.
The five established human HNSCC cell lines used in this study were kindly provided by Dr. Grenman . Cell lines were derived from primary tumors located at the oral cavity (SCC2 and SCC40 cell lines) and larynx (SCC29, SCC38 and SCC42B cell lines). Cells were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 200 μg/ml streptomycin, 2 mM L-glutamine, 20 mM Hepes pH 7.3 and 100 μM non-essential aminoacids. All cells were maintained at 37°C in 5% CO2.
Surgical tissue specimens from 24 patients with HNSCC were obtained, following institutional review board guidelines, from the Hospital Universitario Central de Asturias and Hospital General Universitario de Valencia. All the procedures utilized in this study are in agreement with the 1975 Helsinki Declaration. Informed consent was obtained from each patient. All the patients included in our study underwent surgical resection of their tumor and bilateral neck dissection (functional or radical based on surgical findings). All of them had a single primary tumor; none had undergone treatment prior to surgery, and had microscopically clear surgical margins. A portion of the surgical tissue specimen was sharply excised, placed in sterile tubes, and stored at −80°C in RNAlater (Ambion) for DNA and RNA analysis. Clinically normal adjacent mucosa and normal mucosa from non-cancer patients were also collected. All patients were habitual tobacco and alcohol consumers.
DNA and RNA isolation
Genomic DNA was isolated using the QIAmp DNA Mini kit (Qiagen, Inc., Chatsworth, CA) and subsequently treated with RNase A (1unit/mL) at 37°C for 5 minutes. Total RNA was isolated from HNSCC cell lines and tumour tissues with Nucleospin RNA II (Macherey-Nagel, Easton, PA) following the manufacturer’s instructions with the addition of an extra acid phenol/chloroform extraction followed by RNA precipitation.
Arrays-CGH were performed as described by van den Ijssel et al. . Briefly, tumour cell lines and reference DNAs (pooled from 10 different donors) were differently labelled by random priming. Three hundred ng test and reference DNA were hybridized to an array containing approximately 30,000 DNA oligos spread across the whole genome printed on Codelink activated slides (Amersham Biosciences, Barcelona, Spain). This array contained 29,134 oligos covering 28,830 unique genes. Hybridization and washing took place for two nights in a specialized hybridization chamber (GeneTAC/HybArray12 hybstation; Genomic Solutions/Perkin Elmer). Images were acquired using a Microarray Scanner G2505B (Agilent Technologies). Analysis and data extraction were quantified by BlueFuse (BlueGnome, Cambridge, UK). Gains were defined as at least two neighbouring oligonucleotides with deviations of 0.2 or more from log2 ratio = 0.0. High-level amplification was considered when at least two neighbouring clones reached a log2 ratio of 1.0 or higher.
Oligonucleotides used for real time PCR
Forward: 5′CGCGATAGTCAGGGAGCTGT 3′
Reverse: 5′GGGTTGGCTGGCAAATAGAC 3′
Forward: 5′CACCCCATCTCGAATGATCC 3′
Reverse: 5′GGTGCTGTCTTCGGAACTGC 3′
Forward: 5′TCTCCTGTTGATTCGCAGATGT 3′
Reverse: 5′ TTGAGACCAGTTGATGAATACTCGA 3′
Forward: 5′AACTTCTTGATAACTTGCATGATCTTG 3′
Reverse: 5′AGCAGTACAGATGAAGTTGTTTGACA 3′
Forward: 5′TTCTCATGGATGGAGATGCTCA 3′
Forward: 5′GACTTCCTGAACAGTGTGGATGAG 3′
Reverse: 5′TGCTTTGGTTGATAGTATCACCTGTAT 3′
Forward: 5′CATCCGTCAAGTTCAAGCCA 3′
Reverse: 5′GATAGCAGCTGTTCAAGTAGATGAGG 3′
Forward: 5′TGCTTCATCAGTAACAATCACAACA 3′
Reverse: 5′CCTTTCTTTGCTTCAGAATGCAT 3′
Forward: 5′CCAGGATGATATTAAAGGCATTCA 3′
Reverse: 5′TGAATTACTTCTCTTTCCATATAGTTTCTGA 3′
Forward: 5′CTGCTCTTCAAGGACCGGATT 3′
Reverse: 5′TGTCCGCAAGTGAACCTGC 3′
Forward: 5′GCATTTGGTGCTGGAGGTTT 3′
Reverse: 5′ACCCTTTGTCCATGGTTTGG 3′
Forward: 5′AGTTGATGCAGTTTTCCAGCAA 3′
Reverse: 5′GGTCCACTGAAGACATGGAAGAA 3′
Forward: 5′TGCATCAGGCACCAATTTATTC 3′
Reverse: 5′GAGTGGCCAAGTTCATGAGCA 3′
Forward: 5′TGGACCAACAATTTCAGAGAGTACA 3′
Reverse: 5′TTCATGAGCTGCAACACGATG 3′
Forward: 5′TCTTTGTAGAGGACAAATACTGGAGATT 3′
Reverse: 5′CCATGGAATTTCTCTTCTCATCAA 3′
Forward: 5′CGATGAGGACGAATTCTGGAC 3′
Reverse: 5′CAGTGAGGAACAAGTGGTGCC 3′
Forward: 5′GCCATTACCAGTCTCCGAGG 3′
Reverse: 5′GCAGGCGCCAGAAGAATCT 3′
Forward: 5′GTTCCTGAATTCTTGGTCTATTTTCC 3′
Reverse: 5′CTTCTTTGCCATTTCATTTAGCAAT 3′
Forward: 5′TTGGATCTCAACCTGAATGCC 3′
Reverse: 5′TTGACATTGGGTCCTGAAAGG 3′
Forward: 5′CCTTCTCATTCATTTTGCCCA 3′
Reverse: 5′TCCCAATCACCTTCAGCTCG 3′
Forward: 5′GAACCTGGATTGTGTAGTAATGAAATG 3′
Reverse: 5′TGATCTTCAATGTTCTGGTCTTTCC 3′
Forward: 5′GCTCAAAACCGTGGACCAGT 3′
Reverse: 5′GGCGTGCTGGATGTCATTCT 3′
Forward: 5′AAACTCCTGAAACCGAGCCTG 3′
Reverse: 5′CGCTTTGAGACTCCGGTAGG 3′
Forward: 5′AACCCGAGCAATGTCTGGAA 3′
Reverse: 5′TGATTGAAGTCCTGTCCTCCAA 3′
Forward: 5′GGGATCAGGTACTGCCGTTG 3′
Reverse: 5′TCCTCTTCATTATGCCCAGCA 3′
Forward: 5′CATCTGCACTGCCAGACTGA 3′
Reverse: 5′TTGCCAAACACCACATGCTT 3′
To perform mRNA quantifications, first-strand cDNA was synthesized from 2 μg of total RNA using the Superscript first-strand synthesis system for reverse transcriptase (Invitrogen, Carlsbad, CA) with random primers and oligodT according to the manufacturer’s directions. Cyclophilin was used to normalize for RNA input amounts and to perform relative quantification. To perform genomic DNA amplification, tyrosine hydroxylase gene was used to normalize for DNA input amounts and to perform relative quantification. Melting curve analysis showed a single sharp peak with the expected T m for all samples and genes tested. Relative quantities were obtained using the 2–ΔΔCt method .
Protein extracts were obtained from SCC42B cells at 70% to 80% confluence by scraping on ice in lysis buffer containing 50 mmol/l HEPES (pH 7.9), 250 mmol/l NaCl, 5 mmol/l EDTA, 0.2% NP40, 10% glycerol, and protease inhibitors (0.5 mmol/l phenylmethylsulfonyl fluoride, 1 μg/ml aprotinin, 10 μg/ml leupeptin and 1 mmol/l Na3VO4). Equal amounts of proteins were fractionated on SDS-PAGE and transferred to PVDF membranes. Membranes were probed with anti-TRPC6 antibody (Abcam) or anti-β-actin (Sigma-Aldrich) at 1:100 and 1:5000 dilutions, respectively. Bound antibodies were detected using Enhanced Chemiluminescence Reagent (Amersham Pharmacia Biotech) according to the protocol of the manufacturer.
siRNA duplex oligonucleotides (ON-TARGETplus SMARTpool Human TRPC6) were purchased from Dharmacon Research (Lafayette, CO). siCONTROL Non-targeting pool (Dharmacon) were used as control siRNA. SCC42B cells were transfected with 35 pmol/ml siRNAs using Lipofectamine 2000. TRPC6 mRNA analyses revealed a substantial inhibition (more than 60–70%) of TRPC6 expression 48–72 hours after transfection. The transfected cells were used for subsequent experiments within that interval of time.
Wound healing assay
Cells were grown to confluence in 35-mm tissue culture dishes. Cell monolayers were wounded using a micropipette tip, and floating cells were removed by extensive washing with DMEM. Photographs of the wounded area were taken immediately after making the scratch (0 h time point) and after 8 h using a Leica DMIL microscope to measure the migration rate of cells into the wounded area. At least 15 different fields were randomly chosen across the wound length. For the analysis of the differential cell migration capacity of SCC38, SCC40, and SCC42B cells, the rate of front migration of cell monolayers was analyzed in an AxioObserver.Z1 microscope (Zeiss), equipped with an incubation module, by taking pictures at 0 h and 8 h using an EC Plan-Neofluor 10x/0.30 Ph1 objective.
Matrigel invasion assays
In vitro invasion assays were performed by using a 24-well invasion chamber coated with Matrigel (Becton Dickinson). Cells were trypsinized, washed with PBS, suspended in DMEM containing 5% BSA, and plated in the invasion chamber (3 x 104 cells per well). The lower chambers were filled with DMEM containing 5% BSA with 10% FBS. After 24 h, the cells remaining in the upper chamber were removed by scraping, whereas the cells that invaded through Matrigel were fixed and stained by using 0.5% Crystal Violet in methanol. All invading cells were counted by microscopic visualization. All analyses were performed in triplicate.
MTS-based cell proliferation assay
MTS assays were performed using CellTiter 96 Cell Non-Radioactive Proliferation Assay following the protocol recommended by the manufacturer (Promega, Madison, WI). Briefly, 1000 cells were seeded in each well of 96-well plates, and allowed to growth for 48, 72 or 96 hours. MTS assay was performed at each time point.
Results and discussion
Array CGH analysis of HNSCC-derived cell lines
Most frequently reported chromosomal gains and losses present in HNSCC-derived cell lines
Cell line with minimal region of change
BCL6, EIF4A2, EVI1, GMPS, LPP, MDS1, MLF1, PI3K3CA, RPN1, TFRC, ZNF9
FOXOA3, GOPC, ROS1, STL
ETV1, HOXA9, HOXA11, HOXA13, HNRPA2B1, JAZF1, PMS2
COX6C, EXT1, MYC, NBS1
FANCC, NR4A3, OMD, PTCH1, SYK, TAL2, XPA
PRAD1, NUMA1, PICAM, MAML2, BIRC3
PCM1, FGFR1, WRN, WHSC1L1
CDKN2A, CDKN2B, MLLT3
COPEB, MLLT10, SH3BP1
ATM, CBL, DDX10, PAFAH1B2, POU2AF1, SDHD, ZNF145, FLI1, PRO1073
BCL2, FVT1, SMAD4, MALT1
BCR, CLTCL1, PNUTL1, SMARCB1
Non previously identified altered chromosomal regions
Cell line with minimal region of change
In general, the array CGH data showed that the recurrent genome aberrations described in primary HNSCC tissues are well preserved in the cell lines analyzed here. It also indicates that these cell lines have not accumulated substantial novel recurrent aberrations during extended culture. These data, together with our previous molecular and functional studies [31, 32], suggest that analysis of genomic aberrations in the HNSCC-derived cell lines used here might be a useful approach to identify tumor-associated chromosomal regions substantial for the tumorigenesis and progression of HNSCC.
Impact of focal high-level amplifications on gene expression
To gain some insights into the role of genomic aberrations in HNSCC pathophysiology, we focused in focal amplification events for which it may be easier to pinpoint target genes involved in the pathogenesis of HNSCC.
The present analysis allowed narrowing down and delineating the boundaries of high-level amplification events. Boundaries from the p-telomere span from 95 to 102 Mb (11q21-q22.2), 3,44 to 16,81 Mb (18p11.31-p11.21), 11 to13 Mb (19p13.2-p13.13), and 14,1 to 15,3 Mb (21q11). These are relatively small genomic segments containing 20 or fewer genes (listed in Figure 1) suggesting that any of them may be the target(s) of the amplification. These amplicons do not contain well-established oncogenes in HNSCC. To identify putative driver genes in these genomic regions, we compared the expression levels of candidate genes mapping in the amplicons with their DNA copy number status. Figure 1 illustrates genome-wide copy number plots of the gene amplifications and the gene expression data.
Interestingly, a high degree of correlation between DNA and mRNA levels was found for most of the genes selected at 11q, 18p, 19p, and 21q amplicons. This is in agreement with previous studies showing that amplification has a strong impact on transcription levels [33–35]. Expression of RNMT, MC5R, and MC2R genes at 18p11.31-p11.21 amplicon was significantly up-regulated in SCC40 cells that had shown high-level amplification at that locus, compared with cell lines without gene amplification (p < 0,0001) (Figure 1B). Similarly, the expression levels of the STCH and NRIP1 genes at 21q11 were significantly higher in SCC29 cells, which harbored amplification at that locus, than in the other cell lines without gene alteration (p < 0,01) (Figure 1D). Amplification of the ZNF443, and MAN2B1 genes at 19p13.2-p13.13, detected in SCC42B cells, also correlated with higher expression at the mRNA levels as compared with the other cell lines (p < 0,05) (Figure 1C). However, quantification of the mRNA levels of the JUNB proto-oncogene (19p13.2-p13.13) revealed that SCC42B cells had similar levels of expression than SCC29 cells, which did not show amplification of the 19p13.2-p13.3 locus. These data indicate that ZNF443 and/or MAN2B1 genes, but not JUNB, might be candidates of the selection pressure for structural amplification of the 19p13.2-p13.3 region, at least in SCC42B cells. In general, any of the amplified and over-expressed genes identified here (RNMT, MC5R, MC2R, ZNF443, MAN2B1, NRIP1, and STCH) might be up-regulated in a DNA copy number-dependent manner and could possibly contribute to HNSCC pathogenesis. To our knowledge, no previous evidence is available on the association of these genes in HNSCC biology. Of all the genes analyzed here, only JUNB has been previously found up-regulated at the mRNA and protein level in HNSCC tumour tissues [36–39]. Our data suggest that its over-expression is caused by mechanisms other than gene amplification. Nevertheless, further studies are required to demonstrate unequivocally whether an association exists between the genetic and expression data in tumour tissue samples.
With regard to the 11q21-q22.2 amplicon, recent studies reported high copy number amplification at this locus in HNSCC [12, 13, 30]. This region contains 18 known genes harbouring two gene clusters, one with nine matrix metalloproteinase (MMP) genes, and other with two baculoviral IAP repeat-containing protein (BIRC) genes. Expression analysis of BIRC and MMP genes in the HNSCC-derived cell lines showed no correlation between their mRNA levels and DNA copy number status. In contrast, expression of JRKL, AD031, TRPC6, (Figure 1A), YAP1 and PORIMIN (data not shown) genes were significantly up-regulated in SCC42B cells that had shown high-level amplification at that locus, compared with cell lines without gene amplification (p < 0,01). Specifically, mRNA levels of JRKL, AD031, TRPC6, YAP1, and PORIMIN were, respectively, 30, 50, 600, 10, and 8-fold higher in SCC42B cells than in the other cell lines. mRNA expression of other candidate genes at 11q21-q22.2 amplicon (CNTN5, PGR, and MMP27) was not detected in any of the cell lines. These data exclude CNTN5, PGR, MMP and BIRC genes and point to any of the 5 amplified and over-expressed genes as critical gene-amplification “driver/s”. Of them, only TRPC6 and YAP1 genes have been previously found deregulated in several types of cancer. Amplification and mRNA up-regulation of YAP1 has been previously described in several cancers including HNSCC of the oral cavity [20, 30, 40], sarcomas, meduloblatomas, and mesotheliomas [20, 21, 41, 42]. In addition, recent studies showed that over-expression of YAP1 induces phenotypic alterations that are commonly associated with potent transforming oncogenes [40, 42–44]. TRPC6 is a member of the TRP family of Ca2+- and Na+-permeable channels shown to be up-regulated in glioblastomas and breast, prostate, gastric, and oesophageal cancer cells [23, 45–48]. Our data revealed that this was the most dramatically up-regulated gene in SCC42B cells. However, to the best of our knowledge, up-regulation of TRPC6 has not been previously identified in HNSCC.
TRPC6gene is amplified and over-expressed in HNSCC-tissue specimens
Relative TRPC6 DNA and mRNA levels in HNSCC primary tumors
Genomic TRPC6 DNA levels*
TRPC6 mRNA Levels*
Inhibition of TRPC6expression does not induce changes in SCC42B cell proliferation
Inhibition of TRPC6expression impairs cell migration and invasion
Plasma membrane ion channels contribute to virtually all basic cellular processes and are also involved in the malignant phenotype of cancer cells by modulating different hallmarks of cancer such as proliferation, cellular locomotion, and tissue invasion. Specifically, the morphological and adherence changes of metastatic cells involve Ca2+ signaling supported by enhanced Ca2+ influx. Recently, TRPC6 has emerged as an important player in the control of the aggressive phenotype of glioblastoma cells . Our analysis of the functional significance of TRPC6 overexpression in HNSCC showed that TRPC6 also modulates cell invasion in HNSCC cells. This finding is of interest as it provides the opportunity to therapeutically target TRPC6 to interfere with Ca2+-dependent signaling involved in cell invasion.
In the present study, we report that TRPC6 (11q22) is overexpressed in HNSCC, and provide new evidence that increase in gene dosage is a novel mechanism to activate TRPC6 expression in cancer. Increased TRPC6 mRNA and gene dosage was detected in both, cell lines and tumor tissues, revealing that this molecular alteration can be pathologically relevant in HNSCC. In addition, siRNA-induced knockdown of TRPC6 expression in HNSCC-derived cells dramatically inhibited HNSCC-cell invasion. Therefore, TRPC6 is likely to be a target for amplification that confers enhanced invasive behavior to HNSCC cells and, therefore, may be a promising therapeutic target in the treatment of HNSCC. These data provide the foundation for further functional validation of this putative candidate gene in tumor tissues to determine whether it is crucial for tumor development or progression.
This work was supported by Instituto de Salud Carlos III-Fondo de Investigación Sanitaria [FIS PI11/929 to M.-D.C and C.S.]; Red Temática de Investigación Cooperativa en Cáncer [RD12/0036/0015] Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Economy and Competitiveness & European Regional Development Fund (ERDF); and Obra Social CajAstur-Instituto Universitario de Oncología del Principado de Asturias.
- Akervall J: Genomic screening of head and neck cancer and its implications for therapy planning. Eur Arch Otorhinolaryngol. 2006, 263: 297-304. 10.1007/s00405-006-1039-1.View ArticlePubMedGoogle Scholar
- Squire JA, Bayani J, Luk C, Unwin L, Tokunaga J, MacMillan C, Irish J, Brown D, Gullane P, Kamel-Reid S: Molecular cytogenetic analysis of head and neck squamous cell carcinoma: by comparative genomic hybridization, spectral karyotyping, and expression array analysis. Head Neck. 2002, 24: 874-887. 10.1002/hed.10122.View ArticlePubMedGoogle Scholar
- Perez-Ordonez B, Beauchemin M, Jordan RC: Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol. 2006, 59: 445-453. 10.1136/jcp.2003.007641.View ArticlePubMedPubMed CentralGoogle Scholar
- Tan KD, Zhu Y, Tan HK, Rajasegaran V, Aggarwal A, Wu J, Wu HY, Hwang J, Lim DT, Soo KC, Tan P: Amplification and overexpression of PPFIA1, a putative 11q13 invasion suppressor gene, in head and neck squamous cell carcinoma. Genes Chromosomes Cancer. 2008, 47: 353-362. 10.1002/gcc.20539.View ArticlePubMedGoogle Scholar
- Rodrigo JP, Garcia LA, Ramos S, Lazo PS, Suarez C: EMS1 Gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck. Clin Cancer Res. 2000, 6: 3177-3182.PubMedGoogle Scholar
- Callender T, el-Naggar AK, Lee MS, Frankenthaler R, Luna MA, Batsakis JG: PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. Cancer. 1994, 74: 152-158. 10.1002/1097-0142(19940701)74:1<152::AID-CNCR2820740124>3.0.CO;2-K.View ArticlePubMedGoogle Scholar
- Huang X, Gollin SM, Raja S, Godfrey TE: High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells. Proc Natl Acad Sci U S A. 2002, 99: 11369-11374. 10.1073/pnas.172285799.View ArticlePubMedPubMed CentralGoogle Scholar
- Gorogh T, Weise JB, Holtmeier C, Rudolph P, Hedderich J, Gottschlich S, Hoffmann M, Ambrosch P, Csiszar K: Selective upregulation and amplification of the lysyl oxidase like-4 (LOXL4) gene in head and neck squamous cell carcinoma. J Pathol. 2007, 212: 74-82. 10.1002/path.2137.View ArticlePubMedGoogle Scholar
- Begum A, Imoto I, Kozaki K, Tsuda H, Suzuki E, Amagasa T, Inazawa J: Identification of PAK4 as a putative target gene for amplification within 19q13.12-q13.2 In oral squamous-cell carcinoma. Cancer Sci. 2009, 100: 1908-1916. 10.1111/j.1349-7006.2009.01252.x.View ArticlePubMedGoogle Scholar
- Secades P, Rodrigo JP, Hermsen M, Alvarez C, Suarez C, Chiara MD: Increase in gene dosage is a mechanism of HIF-1alpha constitutive expression in head and neck squamous cell carcinomas. Genes Chromosomes Cancer. 2009, 48: 441-454. 10.1002/gcc.20652.View ArticlePubMedGoogle Scholar
- Singh B, Gogineni SK, Sacks PG, Shaha AR, Shah JP, Stoffel A, Rao PH: Molecular cytogenetic characterization of head and neck squamous cell carcinoma and refinement of 3q amplification. Cancer Res. 2001, 61: 4506-4513.PubMedGoogle Scholar
- Baldwin C, Garnis C, Zhang L, Rosin MP, Lam WL: Multiple microalterations detected at high frequency in oral cancer. Cancer Res. 2005, 65: 7561-7567.PubMedGoogle Scholar
- Roman E, Meza-Zepeda LA, Kresse SH, Myklebost O, Vasstrand EN, Ibrahim SO: Chromosomal aberrations in head and neck squamous cell carcinomas in Norwegian and Sudanese populations by array comparative genomic hybridization. Oncol Rep. 2008, 20: 825-843.PubMedGoogle Scholar
- Weber RG, Sommer C, Albert FK, Kiessling M, Cremer T: Clinically distinct subgroups of glioblastoma multiforme studied by comparative genomic hybridization. Lab Invest. 1996, 74: 108-119.PubMedGoogle Scholar
- Knuutila S, Bjorkqvist AM, Autio K, Tarkkanen M, Wolf M, Monni O, Szymanska J, Larramendy ML, Tapper J, Pere H: DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol. 1998, 152: 1107-1123.PubMedPubMed CentralGoogle Scholar
- Menghi-Sartorio S, Mandahl N, Mertens F, Picci P, Knuutila S: DNA copy number amplifications in sarcomas with homogeneously staining regions and double minutes. Cytometry. 2001, 46: 79-84. 10.1002/cyto.1068.View ArticlePubMedGoogle Scholar
- Imoto I, Tsuda H, Hirasawa A, Miura M, Sakamoto M, Hirohashi S, Inazawa J: Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. Cancer Res. 2002, 62: 4860-4866.PubMedGoogle Scholar
- Dai Z, Zhu WG, Morrison CD, Brena RM, Smiraglia DJ, Raval A, Wu YZ, Rush LJ, Ross P, Molina JR: A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. Hum Mol Genet. 2003, 12: 791-801. 10.1093/hmg/ddg083.View ArticlePubMedGoogle Scholar
- Bashyam MD, Bair R, Kim YH, Wang P, Hernandez-Boussard T, Karikari CA, Tibshirani R, Maitra A, Pollack JR: Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia. 2005, 7: 556-562. 10.1593/neo.04586.View ArticlePubMedPubMed CentralGoogle Scholar
- Helias-Rodzewicz Z, Perot G, Chibon F, Ferreira C, Lagarde P, Terrier P, Coindre JM, Aurias A: YAP1 And VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas. Genes Chromosomes Cancer. 2010, 49: 1161-1171. 10.1002/gcc.20825.View ArticlePubMedGoogle Scholar
- Fernandez LA, Northcott PA, Dalton J, Fraga C, Ellison D, Angers S, Taylor MD, Kenney AM: YAP1 Is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates sonic hedgehog-driven neural precursor proliferation. Genes Dev. 2009, 23: 2729-2741. 10.1101/gad.1824509.View ArticleGoogle Scholar
- Muramatsu T, Imoto I, Matsui T, Kozaki K, Haruki S, Sudol M, Shimada Y, Tsuda H, Kawano T, Inazawa J: YAP is a candidate oncogene for esophageal squamous cell carcinoma. Carcinogenesis. 2010, 32: 389-398.View ArticlePubMedGoogle Scholar
- Chigurupati S, Venkataraman R, Barrera D, Naganathan A, Madan M, Paul L, Pattisapu JV, Kyriazis GA, Sugaya K, Bushnev S: Receptor channel TRPC6 is a key mediator of notch-driven glioblastoma growth and invasiveness. Cancer Res. 2010, 70: 418-427. 10.1158/0008-5472.CAN-09-2654.View ArticlePubMedGoogle Scholar
- Ding X, He Z, Zhou K, Cheng J, Yao H, Lu D, Cai R, Jin Y, Dong B, Xu Y, Wang Y: Essential role of TRPC6 channels in G2/M phase transition and development of human glioma. J Natl Cancer Inst. 2010, 102: 1052-1068. 10.1093/jnci/djq217.View ArticlePubMedGoogle Scholar
- Lansford CDGR, Bier H: Head and neck cancers. 1999, Dordrecht: Kluwer Academic PressGoogle Scholar
- van den Ijssel P, Tijssen M, Chin SF, Eijk P, Carvalho B, Hopmans E, Holstege H, Bangarusamy DK, Jonkers J, Meijer GA: Human and mouse oligonucleotide-based array CGH. Nucleic Acids Res. 2005, 33: e192-10.1093/nar/gni191.View ArticlePubMedPubMed CentralGoogle Scholar
- Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−delta delta C(T)) method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.View ArticlePubMedGoogle Scholar
- Gollin SM: Chromosomal alterations in squamous cell carcinomas of the head and neck: window to the biology of disease. Head Neck. 2001, 23: 238-253. 10.1002/1097-0347(200103)23:3<238::AID-HED1025>3.0.CO;2-H.View ArticlePubMedGoogle Scholar
- Smeets SJ, Braakhuis BJ, Abbas S, Snijders PJ, Ylstra B, van de Wiel MA, Meijer GA, Leemans CR, Brakenhoff RH: Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene. 2006, 25: 2558-2564. 10.1038/sj.onc.1209275.View ArticlePubMedGoogle Scholar
- Snijders AM, Schmidt BL, Fridlyand J, Dekker N, Pinkel D, Jordan RC, Albertson DG: Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene. 2005, 24: 4232-4242. 10.1038/sj.onc.1208601.View ArticlePubMedGoogle Scholar
- Canel M, Secades P, Garzon-Arango M, Allonca E, Suarez C, Serrels A, Frame M, Brunton V, Chiara MD: Involvement of focal adhesion kinase in cellular invasion of head and neck squamous cell carcinomas via regulation of MMP-2 expression. Br J Cancer. 2008, 98: 1274-1284. 10.1038/sj.bjc.6604286.View ArticlePubMedPubMed CentralGoogle Scholar
- Canel M, Secades P, Rodrigo JP, Cabanillas R, Herrero A, Suarez C, Chiara MD: Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number. Clin Cancer Res. 2006, 12: 3272-3279. 10.1158/1078-0432.CCR-05-1583.View ArticlePubMedGoogle Scholar
- Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006, 10: 515-527. 10.1016/j.ccr.2006.10.008.View ArticlePubMedPubMed CentralGoogle Scholar
- Jarvinen AK, Autio R, Kilpinen S, Saarela M, Leivo I, Grenman R, Makitie AA, Monni O: High-resolution copy number and gene expression microarray analyses of head and neck squamous cell carcinoma cell lines of tongue and larynx. Genes Chromosomes Cancer. 2008, 47: 500-509. 10.1002/gcc.20551.View ArticlePubMedGoogle Scholar
- Lockwood WW, Chari R, Coe BP, Girard L, Macaulay C, Lam S, Gazdar AF, Minna JD, Lam WL: DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers. Oncogene. 2008, 27: 4615-4624. 10.1038/onc.2008.98.View ArticlePubMedPubMed CentralGoogle Scholar
- Weber A, Hengge UR, Stricker I, Tischoff I, Markwart A, Anhalt K, Dietz A, Wittekind C, Tannapfel A: Protein microarrays for the detection of biomarkers in head and neck squamous cell carcinomas. Hum Pathol. 2007, 38: 228-238. 10.1016/j.humpath.2006.07.012.View ArticlePubMedGoogle Scholar
- Pacheco MM, Kowalski LP, Nishimoto IN, Brentani MM: Differential expression of c-jun and c-fos mRNAs in squamous cell carcinoma of the head and neck: associations with uPA, gelatinase B, and matrilysin mRNAs. Head Neck. 2002, 24: 24-32. 10.1002/hed.10009.View ArticlePubMedGoogle Scholar
- Xie M, Sun Y, Li Y: Expression of matrix metalloproteinases in supraglottic carcinoma and its clinical implication for estimating lymph node metastases. Laryngoscope. 2004, 114: 2243-2248. 10.1097/01.mlg.0000149467.18822.59.View ArticlePubMedGoogle Scholar
- Werner JA, Rathcke IO, Mandic R: The role of matrix metalloproteinases in squamous cell carcinomas of the head and neck. Clin Exp Metastasis. 2002, 19: 275-282. 10.1023/A:1015531319087.View ArticlePubMedGoogle Scholar
- Zhang L, Ye DX, Pan HY, Wei KJ, Wang LZ, Wang XD, Shen GF, Zhang ZY: Yes-associated protein promotes cell proliferation by activating Fos related activator-1 in oral squamous cell carcinoma. Oral Oncol. 2011, 47: 693-697. 10.1016/j.oraloncology.2011.06.003.View ArticlePubMedGoogle Scholar
- Yokoyama T, Osada H, Murakami H, Tatematsu Y, Taniguchi T, Kondo Y, Yatabe Y, Hasegawa Y, Shimokata K, Horio Y: YAP1 Is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis. 2008, 29: 2139-2146. 10.1093/carcin/bgn200.View ArticlePubMedGoogle Scholar
- Diep CH, Zucker KM, Hostetter G, Watanabe A, Hu C, Munoz RM, Von Hoff DD, Han H: Down-regulation of Yes associated protein 1 expression reduces cell proliferation and clonogenicity of pancreatic cancer cells. PLoS One. 7: e32783-Google Scholar
- Kang W, Tong JH, Chan AW, Lee TL, Lung RW, Leung PP, So KK, Wu K, Fan D, Yu J: Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clin Cancer Res. 2011, 17: 2130-2139. 10.1158/1078-0432.CCR-10-2467.View ArticlePubMedGoogle Scholar
- Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng CX, Brugge JS, Haber DA: Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A. 2006, 103: 12405-12410. 10.1073/pnas.0605579103.View ArticlePubMedPubMed CentralGoogle Scholar
- Guilbert A, Dhennin-Duthille I, Hiani YE, Haren N, Khorsi H, Sevestre H, Ahidouch A, Ouadid-Ahidouch H: Expression of TRPC6 channels in human epithelial breast cancer cells. BMC Cancer. 2008, 8: 125-10.1186/1471-2407-8-125.View ArticlePubMedPubMed CentralGoogle Scholar
- Yue D, Wang Y, Xiao JY, Wang P, Ren CS: Expression of TRPC6 in benign and malignant human prostate tissues. Asian J Androl. 2009, 11: 541-547. 10.1038/aja.2009.53.View ArticlePubMedPubMed CentralGoogle Scholar
- Cai R, Ding X, Zhou K, Shi Y, Ge R, Ren G, Jin Y, Wang Y: Blockade of TRPC6 channels induced G2/M phase arrest and suppressed growth in human gastric cancer cells. Int J Cancer. 2009, 125: 2281-2287. 10.1002/ijc.24551.View ArticlePubMedGoogle Scholar
- Shi Y, Ding X, He ZH, Zhou KC, Wang Q, Wang YZ: Critical role of TRPC6 channels in G2 phase transition and the development of human oesophageal cancer. Gut. 2009, 58: 1443-1450. 10.1136/gut.2009.181735.View ArticlePubMedGoogle Scholar
- Thebault S, Flourakis M, Vanoverberghe K, Vandermoere F, Roudbaraki M, Lehen’kyi V, Slomianny C, Beck B, Mariot P, Bonnal JL: Differential role of transient receptor potential channels in Ca2+ entry and proliferation of prostate cancer epithelial cells. Cancer Res. 2006, 66: 2038-2047. 10.1158/0008-5472.CAN-05-0376.View ArticlePubMedGoogle Scholar
- El Boustany C, Bidaux G, Enfissi A, Delcourt P, Prevarskaya N, Capiod T: Capacitative calcium entry and transient receptor potential canonical 6 expression control human hepatoma cell proliferation. Hepatology. 2008, 47: 2068-2077. 10.1002/hep.22263.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/13/116/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.